相似文献
1
Study of the Genetic Variants in and Non- Genes in a Population-Based Cohort of 2155 Breast/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina.
Cancers (Basel). 2021 May 31;13(11):2711. doi: 10.3390/cancers13112711.
2
Frequency of germline pathogenic variants in breast cancer predisposition genes among young Turkish breast cancer patients.
Breast Cancer Res Treat. 2023 Nov;202(2):297-304. doi: 10.1007/s10549-023-07074-z. Epub 2023 Aug 24.
3
Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions.
Front Genet. 2021 Nov 30;12:674094. doi: 10.3389/fgene.2021.674094. eCollection 2021.
4
NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of -Negative Cases.
Cancers (Basel). 2020 Oct 27;12(11):3140. doi: 10.3390/cancers12113140.
5
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge.
ESMO Open. 2021 Aug;6(4):100235. doi: 10.1016/j.esmoop.2021.100235. Epub 2021 Aug 7.
6
What is the appropriate genetic testing criteria for breast cancer in the Chinese population?-Analysis of genetic and clinical features from a single cancer center database.
Cancer Med. 2023 Jun;12(12):13019-13030. doi: 10.1002/cam4.5976. Epub 2023 Apr 25.
7
Identification and characterization of ATM founder mutation in BRCA-negative breast cancer patients of Arab ethnicity.
Sci Rep. 2023 Nov 27;13(1):20924. doi: 10.1038/s41598-023-48231-0.
8
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17.
9
Identification of a novel pathogenic variant in and genes by a multigene sequencing panel in triple negative breast cancer in Morocco.
J Genomics. 2021 Sep 18;9:43-54. doi: 10.7150/jgen.61713. eCollection 2021.
10
pathogenic variants in triple-negative luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.
Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326. doi: 10.1177/1758835920975326. eCollection 2020.
引用本文的文献
1
Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.
Breast Cancer Res Treat. 2025 Apr;210(2):385-391. doi: 10.1007/s10549-024-07576-4. Epub 2024 Dec 20.
2
The Risk Function of Breast and Ovarian Cancers in the Avrami-Dobrzyński Cellular Phase-Transition Model.
Int J Mol Sci. 2024 Jan 22;25(2):1352. doi: 10.3390/ijms25021352.
3
Landscape of germline variants in breast and ovarian cancer in Peru.
Front Oncol. 2023 Aug 17;13:1227864. doi: 10.3389/fonc.2023.1227864. eCollection 2023.
4
Investigation of germline variants in Bahraini women with breast cancer using next-generation sequencing based-multigene panel.
PLoS One. 2023 Sep 1;18(9):e0291015. doi: 10.1371/journal.pone.0291015. eCollection 2023.
5
Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA.
Int J Mol Sci. 2023 Apr 13;24(8):7235. doi: 10.3390/ijms24087235.
6
Evaluation of genetic alterations in hereditary cancer susceptibility genes in the Ashkenazi Jewish women community of Mexico.
Front Genet. 2023 Feb 10;14:1094260. doi: 10.3389/fgene.2023.1094260. eCollection 2023.
7
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy.
Front Med (Lausanne). 2022 Aug 11;9:894358. doi: 10.3389/fmed.2022.894358. eCollection 2022.
8
PALB2 germline mutations in a multi-gene panel testing cohort of 1905 breast-ovarian cancer patients in Argentina.
Breast Cancer Res Treat. 2022 Jul;194(2):403-412. doi: 10.1007/s10549-022-06620-5. Epub 2022 May 24.
本文引用的文献
1
Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.
Drug Saf. 2021 Jul;44(7):725-732. doi: 10.1007/s40264-021-01071-1. Epub 2021 May 6.
2
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
JAMA Oncol. 2021 Feb 1;7(2):230-237. doi: 10.1001/jamaoncol.2020.6252.
3
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
JAMA Oncol. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134.
4
Triple-negative breast cancer molecular subtyping and treatment progress.
Breast Cancer Res. 2020 Jun 9;22(1):61. doi: 10.1186/s13058-020-01296-5.
5
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.
6
Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes.
Mayo Clin Proc. 2019 Jun;94(6):1084-1098. doi: 10.1016/j.mayocp.2019.02.017.
7
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Hum Genomics. 2018 Aug 13;12(1):39. doi: 10.1186/s40246-018-0171-5.
8
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Hum Mutat. 2018 May;39(5):593-620. doi: 10.1002/humu.23406. Epub 2018 Mar 12.
9
Triple-negative breast cancer and the potential for targeted therapy.
Pharmacogenomics. 2017 Nov;18(17):1595-1609. doi: 10.2217/pgs-2017-0117. Epub 2017 Nov 2.
10
Spectrum of BRCA1/2 variants in 940 patients from Argentina including novel, deleterious and recurrent germline mutations: impact on healthcare and clinical practice.
Oncotarget. 2016 Jul 24;8(36):60487-60495. doi: 10.18632/oncotarget.10814. eCollection 2017 Sep 1.
Zotero 插件